Are aromatase inhibiors and chemotheraphy associated with cognitive decline among breast cancer survivors? Findings from a large case/control study

2010 ◽  
Author(s):  
B. Wood ◽  
L. Gallicchio ◽  
R. MacDonald ◽  
S. A. Appling ◽  
K. J. Helzlsouer
Pain Medicine ◽  
2014 ◽  
Vol 15 (10) ◽  
pp. 1715-1723 ◽  
Author(s):  
Elena Caro-Morán ◽  
Lourdes Díaz-Rodríguez ◽  
Irene Cantarero-Villanueva ◽  
Noelia Galiano-Castillo ◽  
Manuel Arroyo-Morales ◽  
...  

Author(s):  
Angela Chetrit ◽  
Sivan Ben-Avraham ◽  
Lori Mandelzweig ◽  
Tova Amitai ◽  
Nava Siegelmann Danieli ◽  
...  

2016 ◽  
Vol 52 (1) ◽  
pp. 54-63 ◽  
Author(s):  
Denis E. O'Donnell ◽  
Katherine A. Webb ◽  
Daniel Langer ◽  
Amany F. Elbehairy ◽  
J. Alberto Neder ◽  
...  

Climacteric ◽  
2019 ◽  
Vol 22 (2) ◽  
pp. 202-207 ◽  
Author(s):  
M. Terra Branco ◽  
D. de Araujo Brito Buttros ◽  
E. Carvalho-Pessoa ◽  
M. Lima Sobreira ◽  
C. Yukie Nakano Schincariol ◽  
...  

2018 ◽  
Vol 4 (Supplement 2) ◽  
pp. 103s-103s
Author(s):  
H.S. Mohd Hashim ◽  
C. Lim ◽  
N.I. Junazli ◽  
S.L. Choo ◽  
K.Y. Low ◽  
...  

Background: One of the positive outcomes of improvements in cancer care is the increasing number of people who survive the disease. Worldwide, the number of cancer survivors will continue to increase, with a threefold increase predicted from 25 million in 2008 to 75 million in 2030. Breast cancer survivors have the highest survival rates compared other types of cancer. Following a diagnosis of breast cancer, issues that women often worry about include the possibility of cancer recurrence, challenges with reacclimatizing to daily life posttreatment completion and numerous other emotional and physical challenges. It is unknown whether over time the coping skills of these survivors enable them to have a similar quality of life (QOL) as other normal women. This study aimed to assess and compare the quality of life (QOL) among breast cancer survivors and nonbreast cancer survivors in the Klang Valley, Malaysia. Methods: This case-control study used the European Organization for Research and Treatment of Cancer - Quality of Life Questionnaire (EORTC-QLQ) to ascertain QOL within breast cancer survivors and nonbreast cancer survivors. Simple random sampling was used to identify i) participants from the case arm -from four cancer-related NGOs in the Klang Valley; and ii) participants from the control arm - from women attending Kuala Lumpur Hospital. 176 number of participants were involved in this study with a 1:1 ratio. Result: There was no significant difference in quality of life (QOL) between breast cancer survivors and nonbreast cancer survivors in the Klang Valley, Malaysia. The longer the period of survival (5 years and above), the higher the QOL levels in breast cancer survivors. Conclusion: In conclusion, women with breast cancer especially those who had survived more than 5 years, had similar quality of life (QOL) levels as women who did not suffer from the disease. Women with breast cancer may have developed additional coping skills which could be taught to other patients living with cancer or even those with other chronic illnesses.


2015 ◽  
Vol 18 (4) ◽  
pp. 378 ◽  
Author(s):  
Raffaella Marcheselli ◽  
Luigi Marcheselli ◽  
Laura Cortesi ◽  
Alessia Bari ◽  
Claudia Cirilli ◽  
...  

2019 ◽  
Vol 28 (4) ◽  
pp. 822-825 ◽  
Author(s):  
Brennan Decker ◽  
Jamie Allen ◽  
Craig Luccarini ◽  
Karen A. Pooley ◽  
Mitul Shah ◽  
...  

2021 ◽  
Author(s):  
Clara Sebbag ◽  
Christine Rousset-Jablonski ◽  
Florence Coussy ◽  
Isabelle Ray-Coquard ◽  
Clementine Garin ◽  
...  

Objective: To compare the prevalence of contraception in breast cancer (BC) patients at risk of unintentional pregnancy (i.e. not currently pregnant or trying to get pregnant) and matched controls. Design: The FEERIC study (Fertility, Pregnancy, Contraception after BC in France) is a prospective, multicenter case-control study. Data were collected through online questionnaires completed on the Seintinelles* research platform. Setting: Not applicable Patient(s): BC patients aged from 18 to 43 years, matched for age and parity to cancer free volunteer controls in a 1:2 ratio. Intervention(s): None Results: In a population of 1278 women at risk of unintentional pregnancy, the prevalence of contraception at study inclusion did not differ significantly between cases (340/431, 78.9%) and controls (666/847, 78.6%, p=0.97). However, the contraceptive methods used were significantly different, with a higher proportion of copper IUD use in BC survivors (59.5% versus 25.0% in controls p<0.001). For patients at risk of unintentional pregnancy, receiving information about chemotherapy induced ovary damage at BC diagnosis (OR= 2.47 95%CI [ 1.39 - 4.37] and anti-HER2 treatment (OR=2.46, 95% CI [ 1.14 - 6.16]) were significantly associated with the use of a contraception in multivariate analysis. Discussion: In this large French study, BC survivors had a prevalence of contraception use similar to that for matched controls, though almost one in five women at risk of unintentional pregnancy did not use contraception. Dedicated consultations at cancer care centers could further improve access to information and contraception counseling.


Sign in / Sign up

Export Citation Format

Share Document